Blog – Clinical Trial Results

Atrial fibrillation affects up to 70% of patients with ATTR-CM—but how does it impact treatment outcomes?

July 1, 2026

Dr. Brett Sperry and Dr. C. Michael Gibson discuss new findings showing that acoramidis delivered consistent clinical benefits regardless of […]

Women don’t always present with the “classic” signs of heart disease—and that can have serious consequences. Dr. Malissa Wood and Dr. C. Michael Gibson discuss the gaps in women’s cardiovascular care and why CCTA is emerging as a powerful tool for earlier, more accurate diagnosis.

June 17, 2026

Sponsored by Heartflow

When we think of CT angio we usually think of risk stratification, prevention and diagnosis.

June 11, 2026

But CT angio can also be used to plan your PCI procedures ! Dr. Evan Shlofmitz and Dr. C. Michael […]

Dr. Ahmad Masri and Dr. C Michael Gibson discuss outpatient worsening heart failure in transthyretin amyloid cardiomyopathy in the Attribute-CM trial

May 29, 2026

Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.

Dr. Eugene Brailovsky and Dr. C. Michael Gibson discuss: AF Outcomes and Cardiac Conduction Abnormalities In ATTRibute-CM

May 19, 2026

Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.

Dr. Steve Nissen and Dr. C. Michael Gibson discuss how management is evolving beyond statins alone—highlighting earlier combination therapy, lower LDL-C goals, and expanded roles for non-statin therapy

April 21, 2026

Sponsored by Esperion Therapeutics Inc., who did not influence the content of the presentation

Dr. Neha Pagidipati and Dr. C. Michael Gibson discuss how the new lipid guidelines are moving the needle on LDL lowering: earlier, lower, longer.

April 20, 2026

The recent Vesalius trial adds to the data supporting lower is better, and suggests that even lower (an achieved LDL of 45 […]

Dr. Prem Soman and Dr. C. Michael Gibson Discuss: Long-Term Survival Benefits and Disease Stabilization With Acoramidis In Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

March 30, 2026

Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.

Dr. Victoria Parikh and Dr. C. Michael Gibson Discuss: Safety and Preliminary Efficacy of AAVrh.10hPKP2 (LX2020) Gene Therapy in PKP2- Arrhythmogenic Cardiomyopathy

March 30, 2026

Disclosures TBD

Dr. Scott Solomon and Dr. C. Michael Gibson Discuss: The Npr1 Agonist Xxb750 in Heart Failure

March 30, 2026

Disclosures TBD